Microglia and Interleukin-1&bgr; in Ischemic Retinopathy Elicit Microvascular Degeneration Through Neuronal Semaphorin-3A

Objective—Proinflammatory cytokines contribute to the development of retinal vasculopathies. However, the role of these factors and the mechanisms by which they elicit their effects in retina are not known. We investigated whether activated microglia during early stages of ischemic retinopathy produces excessive interleukin-1&bgr; (IL-1&bgr;), which elicits retinal microvascular degeneration not directly but rather by triggering the release of the proapoptotic/repulsive factor semaphorin-3A (Sema3A) from neurons. Approach and Results—Sprague Dawley rats subjected to retinopathy induced by hyperoxia (80% O2; O2-induced retinopathy) exhibited retinal vaso-obliteration associated with microglial activation, NLRP3 upregulation, and IL-1&bgr; and Sema3A release; IL-1&bgr; was mostly generated by microglia. Intraperitoneal administration of IL-1 receptor antagonists (Kineret, or rytvela [101.10]) decreased these effects and enhanced retinal revascularization; knockdown of Sema3A resulted in microvessel preservation and, conversely, administration of IL-1&bgr; caused vaso-obliteration. In vitro, IL-1&bgr; derived from activated primary microglial cells, cultured under hyperoxia, stimulated the release of Sema3A in retinal ganglion cells-5, which in turn induced apoptosis of microvascular endothelium; antagonism of IL-1 receptor decreased microglial activation and on retinal ganglion cells-5 abolished the release of Sema3A inhibiting ensuing endothelial cell apoptosis. IL-1&bgr; was not directly cytotoxic to endothelial cells. Conclusions—Our findings suggest that in the early stages of O2-induced retinopathy, retinal microglia are activated to produce IL-1&bgr;, which sustains the activation of microglia and induces microvascular injury through the release of Sema3A from adjacent neurons. Interference with IL-1 receptor or Sema3A actions preserves the microvascular bed in ischemic retinopathies and, consequently, decreases ensued pathological preretinal neovascularization.

[1]  R. Morita,et al.  Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain , 2012, Nature Medicine.

[2]  V. Narendran,et al.  Aggressive posterior retinopathy of prematurity in large preterm babies in South India , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[3]  E. Ling,et al.  Roles of Activated Microglia in Hypoxia Induced Neuroinflammation in the Developing Brain and the Retina , 2012, Journal of Neuroimmune Pharmacology.

[4]  Laure Gambardella,et al.  A Computational Tool for Quantitative Analysis of Vascular Networks , 2011, PloS one.

[5]  H. Agostini,et al.  Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy , 2011, Journal of Neuroinflammation.

[6]  Hong Zhang.  Anti-IL-1β therapies. , 2011, Recent Patents on DNA & Gene Sequences.

[7]  Lois E. H. Smith,et al.  Ghrelin modulates physiologic and pathologic retinal angiogenesis through GHSR-1a. , 2011, Investigative ophthalmology & visual science.

[8]  C. Luu,et al.  Retinal ganglion cell death is induced by microglia derived pro‐inflammatory cytokines in the hypoxic neonatal retina , 2011, The Journal of pathology.

[9]  X. Guillonneau,et al.  Interleukin-1β inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration. , 2011, The American journal of pathology.

[10]  Lois E. H. Smith,et al.  Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. , 2011, Blood.

[11]  E. Kavanagh,et al.  Caspase signalling controls microglia activation and neurotoxicity , 2011, Nature.

[12]  H. Kettenmann,et al.  Physiology of microglia. , 2011, Physiological reviews.

[13]  S. Reddy,et al.  CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. , 2010, The Journal of clinical investigation.

[14]  Y. Carmi,et al.  The Role of Macrophage-Derived IL-1 in Induction and Maintenance of Angiogenesis1 , 2009, The Journal of Immunology.

[15]  A. Stahl,et al.  Computer-aided quantification of retinal neovascularization , 2009, Angiogenesis.

[16]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[17]  C. Dinarello,et al.  Intravitreal Anakinra Inhibits Choroidal Neovascular Membrane Growth in a Rat Model , 2009, Ocular immunology and inflammation.

[18]  P. Hardy,et al.  Interleukin-1 and ischemic brain injury in the newborn: development of a small molecule inhibitor of IL-1 receptor. , 2008, Seminars in perinatology.

[19]  A. Pshezhetsky,et al.  Development of a Novel Noncompetitive Antagonist of IL-1 Receptor1 , 2008, The Journal of Immunology.

[20]  W. Green,et al.  Microglial activation in human diabetic retinopathy. , 2008, Archives of ophthalmology.

[21]  G. Neufeld,et al.  Semaphorin-3A and Semaphorin-3F Work Together to Repel Endothelial Cells and to Inhibit Their Survival by Induction of Apoptosis* , 2007, Journal of Biological Chemistry.

[22]  T. Langmann.  Microglia activation in retinal degeneration , 2007, Journal of leukocyte biology.

[23]  S. Mohr,et al.  Inhibition of Caspase-1/Interleukin-1β Signaling Prevents Degeneration of Retinal Capillaries in Diabetes and Galactosemia , 2007, Diabetes.

[24]  S. Kadayıfçılar,et al.  Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. , 2006, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[25]  S. Sizmaz,et al.  Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy , 2006, Eye.

[26]  M. Leduc,et al.  Potential role of microglia in retinal blood vessel formation. , 2006, Investigative ophthalmology & visual science.

[27]  N. Rothwell,et al.  Interleukin‐1‐induced neurotoxicity is mediated by glia and requires caspase activation and free radical release , 2006, Journal of neurochemistry.

[28]  M. R. Powers,et al.  Microglia and macrophages are increased in response to ischemia-induced retinopathy in the mouse retina. , 2006, Molecular vision.

[29]  N. Rothwell,et al.  Neuroprotective actions of endogenous interleukin‐1 receptor antagonist (IL‐1ra) are mediated by glia , 2006, Glia.

[30]  R. Strieter,et al.  Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. , 2005, The Journal of clinical investigation.

[31]  N. Rothwell,et al.  Interleukin-1 and neuronal injury , 2005, Nature Reviews Immunology.

[32]  Y. Toiyama,et al.  Interleukin-1 Receptor Antagonist Inhibits the Expression of Vascular Endothelial Growth Factor in Colorectal Carcinoma , 2005, Oncology.

[33]  T. Gardner,et al.  Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. , 2005, Diabetes.

[34]  S. Levison,et al.  Interleukin-1 and the Interleukin-1 Type 1 Receptor are Essential for the Progressive Neurodegeneration that Ensues Subsequent to a Mild Hypoxic/Ischemic Injury , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  P. Hardy,et al.  Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy. , 2004, Free radical biology & medicine.

[36]  R. Kowluru,et al.  Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. , 2004, Investigative ophthalmology & visual science.

[37]  S. Levison,et al.  Interleukin‐1: A master regulator of neuroinflammation , 2004, Journal of neuroscience research.

[38]  B. Rouse,et al.  Counteracting corneal immunoinflammatory lesion with interleukin‐1 receptor antagonist protein , 2004, Journal of leukocyte biology.

[39]  R. Kowluru,et al.  Role of interleukin-1β in the pathogenesis of diabetic retinopathy , 2004, British Journal of Ophthalmology.

[40]  S. Segal,et al.  Differential Effects of IL-1α and IL-1β on Tumorigenicity Patterns and Invasiveness 1 , 2003, The Journal of Immunology.

[41]  Y. Ogura,et al.  Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease , 2003, Nature Medicine.

[42]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Archer,et al.  The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. , 2002, Investigative ophthalmology & visual science.

[44]  R. Blaheta,et al.  Interleukin‐4, interleukin‐10, and interleukin‐1‐receptor antagonist but not transforming growth factor‐β induce ramification and reduce adhesion molecule expression of rat microglial cells , 2002, Journal of neuroscience research.

[45]  M. Kuwano,et al.  Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFα and IL‐1α , 2000 .

[46]  V. Gagliardini,et al.  Semaphorin III Can Induce Death in Sensory Neurons , 1999, Molecular and Cellular Neuroscience.

[47]  Y. Fukuuchi,et al.  Microglia-specific localisation of a novel calcium binding protein, Iba1. , 1998, Brain research. Molecular brain research.

[48]  C. Gabay,et al.  Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. , 1997, The Journal of clinical investigation.

[49]  G. Kreutzberg.  Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[50]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[51]  M. Hangai,et al.  Interleukin-1 gene expression in transient retinal ischemia in the rat. , 1995, Investigative ophthalmology & visual science.

[52]  C. Dinarello,et al.  The biological properties of interleukin-1. , 1994, European cytokine network.

[53]  J. Penn,et al.  Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. , 1994, Investigative ophthalmology & visual science.

[54]  A. Reder,et al.  Cytokines in the vitreous of patients with proliferative diabetic retinopathy. , 1992, American journal of ophthalmology.

[55]  T. Molitor,et al.  Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. , 1992, Journal of immunology.

[56]  J. Relton,et al.  Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat , 1992, Brain Research Bulletin.

[57]  A. Mantovani,et al.  Cytokine regulation of endothelial cell function , 1992, Behring Institute Mitteilungen.

[58]  C. J. Dunn,et al.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein , 1990, Nature.

[59]  I. Hemo,et al.  In vivo angiogenic activity of interleukins. , 1990, Archives of ophthalmology.

[60]  A. Garner,et al.  Vaso-obliteration and retrolental fibroplasia. , 1971, Proceedings of the Royal Society of Medicine.

[61]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[62]  H. Forman,et al.  Glutathione, stress responses, and redox signaling in lung inflammation. , 2005, Antioxidants & redox signaling.

[63]  P. Hardy,et al.  Inflammatory lipid mediators in ischemic retinopathy. , 2005, Pharmacological reports : PR.

[64]  R. Kowluru,et al.  Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. , 2004, The British journal of ophthalmology.

[65]  M. Kuwano,et al.  Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. , 2000, International journal of cancer.

[66]  R. Caldwell,et al.  Isolation and culture of retinal microglia. , 1993, Current eye research.